Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;4(2):37-42.
doi: 10.1016/j.prnil.2016.05.001. Epub 2016 May 17.

New drugs in prostate cancer

Sangjun Yoo  1 , Se Young Choi  1 , Dalsan You  1 , Choung-Soo Kim  1
Affiliations
Review

New drugs in prostate cancer

Sangjun Yoo et al. Prostate Int. 2016 Jun.

Abstract

The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other treatments are slim, and the need for new agents persists. In recent years, novel agents, including abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, have been approved for the treatment of CRPC, and more such agents based on diverse mechanisms are under investigation or evaluation. In this article, the authors reviewed the current literature on recent advances in medical treatment of prostate cancer, especially CRPC. In addition, the authors elaborated on novel drugs for prostate cancer currently undergoing investigation and their mechanisms.

Keywords: Castration Resistant; Drug Therapy; Drugs; Investigational; Prostatic Neoplasm.

PubMed Disclaimer

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
    1. Ross R.W., Xie W., Regan M.M., Pomerantz M., Nakabayashi M., Daskivich T.J. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112:1247–1253. - PubMed
    1. Egan A., Dong Y., Zhang H., Qi Y., Balk S.P., Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014;40:426–433. - PubMed
    1. Wright J.L., Kwon E.M., Ostrander E.A., Montgomery R.B., Lin D.W., Vessella R. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2011;20:619–627. - PMC - PubMed
    1. Yang M., Xie W., Mostaghel E., Nakabayashi M., Werner L., Sun T. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29:2565–2573. - PMC - PubMed